Jason Thompson, MD
Cardiovascular Disease · Birmingham, ALNPI 1740236694
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $233,852 of the $247,677 with a category attached, or 94.4%. Novo Nordisk accounts for 92.5% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $71,311, 7.8 times the $9,097 reported in 2019. Among cardiovascular disease clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 286 payments — averaging $866.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$229K
- Medtronic$8K
- Esperion Therapeutics, Inc.$8K
- Novartis$542
- Abbott$360
- Boehringer Ingelheim$316
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$233,85294%
- Travel & lodging$7,5863%
- Food & beverage$6,2393%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 110 | $229,147 |
| Medtronic(2 entities) | 18 | $8,245 |
| Esperion Therapeutics, Inc. | 7 | $7,515 |
| Novartis | 42 | $542 |
| Abbott | 6 | $360 |
| Boehringer Ingelheim | 18 | $316 |
| Johnson & Johnson | 19 | $261 |
| Pfizer | 11 | $185 |
| Amgen | 10 | $155 |
| Sanofi-aventis U.S. LLC | 9 | $154 |
| E.r. Squibb & Sons, L.L.C. | 9 | $145 |
| Merck | 8 | $139 |
| Organogenesis Inc. | 1 | $118 |
| Abiomed | 2 | $95 |
| Amarin Pharma, Inc. | 3 | $58 |
| AstraZeneca | 3 | $42 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Lantheus Medical Imaging, Inc. | 1 | $35 |
| Biocompatibles, Inc. | 2 | $30 |
| Atricure, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Bayer | 1 | $15 |
| Z-medica, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$247,677 in reported general payments places this provider in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 702 | $567,610 |
| CamzyosMavacamten | 21 | $174,090 |
| JardianceEmpagliflozin | 152 | $142,290 |
| XareltoRivaroxaban | 121 | $87,120 |
| EntrestoSacubitril/Valsartan | 70 | $64,219 |
| Repatha SureclickEvolocumab | 56 | $39,125 |
| MounjaroTirzepatide | 33 | $33,450 |
| OzempicSemaglutide | 29 | $32,702 |
| Repatha SyringeEvolocumab | 31 | $24,230 |
| Ranolazine ErRanolazine | 217 | $21,900 |
| MultaqDronedarone Hcl | 11 | $18,413 |
| Flecainide Acetate | 196 | $8,985 |
| BrilintaTicagrelor | 18 | $8,739 |
| Nebivolol Hcl | 136 | $8,720 |
| Bumetanide | 341 | $8,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $185 | $567,610702 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $145 | $174,09021 claims |
| Boehringer IngelheimJardiance, Pradaxa | $316 | $144,516164 claims |
| Johnson & JohnsonXarelto | $261 | $87,120121 claims |
| NovartisEntresto | $542 | $64,21970 claims |
| Novo NordiskOzempic | $229,147 | $32,70229 claims |
| Sanofi-aventis U.S. LLCMultaq | $154 | $18,41311 claims |
| AstraZenecaBrilinta | $42 | $8,73918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Birmingham
- Vikram AroraBirmingham$271K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Thomas CawthonBirmingham$54K
- Weihan ChenBirmingham$51K
- Farrell MendelsohnBirmingham$51K
- Charles MooreBirmingham$47K
- Christopher DegroatBirmingham$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.